Eye Diseases > Eyelids
Basal Cell Carcinoma (Eyelid)
Practical clinical guide to periocular basal cell carcinoma (BCC): risk recognition, diagnosis, treatment strategy, margin control principles, reconstruction planning, and long-term surveillance.
Figure: Classic nodular periocular BCC with pearly rolled border, central ulceration, and telangiectasia. Suspicious lesions require biopsy and definitive treatment with histologic margin control.
- Ultraviolet radiation (UV): principal etiologic driver (cumulative UV damage).
- Genetic susceptibility: PTCH1/SMO pathway dysregulation (hedgehog signaling).
- Prior ionizing radiation or arsenic exposure: uncommon but documented contributors.
- Immunosuppression: increases skin cancer burden and aggressive behavior risk.
- Syndromic predisposition: basal cell nevus syndrome (Gorlin syndrome).
- UV-mediated DNA injury: cumulative mutational burden in basal keratinocytes.
- Hedgehog pathway activation: loss of PTCH1 inhibition or SMO activation drives proliferation.
- Tumor nest formation: basaloid cell islands with peripheral palisading and stromal retraction.
- Local tissue infiltration: progressive horizontal and vertical spread along tissue planes.
- Subtype behavior: infiltrative/morpheaform variants show greater subclinical extension.
By histologic subtype
- Nodular: most common periocular subtype.
- Superficial: erythematous scaly plaque; less common on eyelids.
- Infiltrative / morpheaform: poorly defined margins, higher recurrence risk.
- Micronodular: deeper extension potential.
- Basosquamous: more aggressive behavior profile.
By anatomic risk zone
- Lower lid (most common site).
- Medial canthus (high-risk due to deep tissue pathways).
- Upper lid / lateral canthus (less common).
By stage (AJCC periocular framework)
- Localized, locally advanced, orbital invasion, rare metastatic disease.
- Fair skin (Fitzpatrick I-II), light eyes/hair, and poor tanning response.
- High cumulative sun exposure and history of sunburns.
- Older age and male sex in many epidemiologic cohorts.
- Previous skin cancer history (BCC/SCC/melanoma).
- Immunosuppression (transplant, chronic immunosuppressants).
- Radiation exposure and genetic syndromes (e.g., Gorlin syndrome).
- Pearly papule or nodule with rolled border.
- Surface telangiectasia on or around lesion.
- Central ulceration/crusting ("rodent ulcer") in advanced lesions.
- Localized lash loss (madarosis) and lid margin distortion.
- Induration or scar-like plaque in infiltrative/morpheaform BCC.
- Often asymptomatic in early disease.
- Non-healing "sore" or recurrent scab at lid margin/medial canthus.
- Intermittent bleeding, crusting, or irritation.
- Cosmetic change noticed by patient/family.
- Late symptoms: discomfort, tearing, ocular irritation, visual disturbance from lid malposition.
- Progressive local tissue destruction (skin, tarsus, canthal tendons).
- Lid malposition: ectropion, entropion, lagophthalmos, exposure keratopathy.
- Canalicular/lacrimal system involvement with epiphora.
- Perineural spread (uncommon but clinically significant).
- Orbital invasion in neglected or aggressive subtypes.
- Recurrence after incomplete excision.
Eyelid BCC is primarily a locally invasive malignancy with very low metastatic potential. Systemic complications are rare; the major burden is regional tissue destruction.
- Syndromic association: Gorlin syndrome may present with multiple early-onset BCCs.
- Immunosuppression: can increase multiplicity and recurrence risk.
- Metastasis: exceptionally rare in BCC, but locally advanced disease can be morbid.
- Clinical suspicion: non-healing pearly/ulcerative lid lesion.
- Biopsy confirmation: incisional, punch, or excisional biopsy based on lesion size/site.
- Histopathology: basaloid nests, peripheral palisading, stromal retraction artifact.
- Risk stratification: subtype, size, location (medial canthus high risk), prior recurrence.
- Imaging (CT/MRI): if deep invasion, canthal/orbital extension, or perineural spread is suspected.
Imaging Findings
- Dermoscopy: arborizing telangiectasia (branching vessels), blue-grey ovoid nests, spoke-wheel structures, and ulceration with white structureless area in nodular BCC.
- MRI (orbit/skull base): indicated for suspected perineural invasion; assess orbital apex and pterygopalatine fossa in medial canthal and infiltrative lesions.
- High-frequency ultrasound: for depth assessment pre-operatively in selected cases.
Staging & Risk Classification
| AJCC T-Stage | Criteria | Risk |
|---|---|---|
| T1 | <2 cm, no high-risk features | Low |
| T2 | 2–4 cm or high-risk features (perineural invasion, depth, morpheaform subtype) | Moderate |
| T3 | >4 cm or deep structure invasion | High |
| T4 | Bone, orbital, or skull base invasion | Very High |
| BCC Subtype | Risk Profile | Margin Strategy |
|---|---|---|
| Nodular | Low–moderate | Standard excision acceptable |
| Superficial | Low | Standard excision acceptable |
| Morpheaform / Infiltrative | High (extensive subclinical spread) | Mohs or frozen section mandatory |
| Basosquamous | High (metastatic potential) | Mohs preferred |
Singapore Optometry Scope Note: All suspected periocular basal cell carcinomas require urgent referral to ophthalmology or oculoplastics for biopsy and surgical management. Optometrists play a critical role in early detection and timely referral. Do not delay referral for suspicious eyelid lesions.
First-line definitive treatment
- Margin-controlled excision: Mohs micrographic surgery or frozen-section-guided excision.
- Goal: complete tumor removal with maximal tissue preservation.
- Reconstruction: staged based on defect size, lamellar involvement, and canthal anatomy.
Alternative/adjunctive options
- Radiotherapy: selected non-surgical candidates or adjuvant setting.
- Topical/ablative modalities: generally limited role for high-risk periocular lesions.
- Systemic hedgehog inhibitors (e.g., vismodegib/sonidegib): for unresectable/advanced disease.
Follow-up
- Regular surveillance for local recurrence and new primary skin cancers.
- Sun-protection counselling and skin self-monitoring.
- Coordinate dermatology/oculoplastic oncology follow-up in high-risk cases.
- Excellent when detected early and completely excised.
- Cure rates are high with margin-controlled surgery.
- Recurrence risk increases with infiltrative subtype, positive margins, medial canthus location, and prior recurrence.
- Delay in treatment worsens morbidity through local destructive spread.
- Squamous cell carcinoma: hyperkeratotic, indurated, more aggressive metastatic potential.
- Sebaceous carcinoma: yellowish thickening, recurrent chalazion-like lesion, madarosis.
- Keratoacanthoma: rapid growth with central keratin plug.
- Actinic keratosis / Bowen disease: scaly dysplastic surface lesions.
- Chalazion/chronic blepharitis: inflammatory mimics, especially early lesions.
- Intradermal nevus / papilloma: benign nodules lacking ulcerative-destructive behavior.
- Amelanotic melanoma (rare): atypical vascular nonpigmented malignant lesion.
Loss of lid margin architecture — notching, irregularity, or focal madarosis — is a high-risk sign that should trigger urgent biopsy referral.
Morpheaform BCC extends subclinically far beyond the visible margin. Clinical estimation of excision boundaries is unreliable; Mohs micrographic surgery is the preferred margin-control technique.
Medial canthal BCC warrants MRI before surgery to assess perineural spread to the orbital apex and pterygopalatine fossa, even when the lesion appears small clinically.
Never treat without histopathology. Presumptive treatment of an eyelid lesion risks inadequate management of an undiagnosed malignancy — biopsy first; plan treatment after confirmed pathology.
Upper eyelid BCC is less common than lower lid BCC but tends to be more aggressive, with greater risk of orbital and lacrimal system involvement.
Pigmented BCC can mimic melanoma on dermoscopy; both show blue-grey structures, but BCC typically lacks the brown pseudopod network of melanoma. Biopsy is required for definitive differentiation.
Singapore Optometry Scope Note: Document all suspicious periocular lesions with standardised close-up photographs before referral. Refer for histopathological assessment — optometrists in Singapore do not perform biopsy or excision. Include lesion size, site, duration, and any lash loss in the referral letter.
- American Academy of Ophthalmology. Basic and Clinical Science Course (BCSC), Section 7: Orbit, Eyelids, and Lacrimal System. Latest edition.
- Cook BE Jr, Bartley GB. Epidemiologic characteristics and clinical course of eyelid and periocular basal cell carcinoma. Ophthalmic Plast Reconstr Surg.
- Deprez M, Uffer S. Clinicopathological features of eyelid skin tumors: a large retrospective series. Br J Ophthalmol.
- Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R. Basal cell carcinoma treated with Mohs micrographic surgery in the periocular region.
- Sullivan TJ, Whitehead KJ, Williamson R, et al. Management outcomes in periocular BCC with margin-controlled excision.
- NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer. Latest update.
- European interdisciplinary guideline on diagnosis and treatment of basal cell carcinoma. Latest update.
- Dika E, Scarfì F, Ferracin M, et al. Basal cell carcinoma pathogenesis and molecular pathways (hedgehog signaling review).
- Sekulic A, Migden MR, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-2179.
- Arits AHMM, et al. Recurrence rates and risk factors after treatment of periocular BCC: systematic evidence.
- British Oculoplastic Surgery Society guidance: suspicious eyelid lesion pathways and referral standards.
- UpToDate. Basal cell carcinoma of the skin and periocular management principles (accessed 2026).